Top 10 drugs under research of Fosun medicine

It was once said that if Hengrui is China's Pfizer, then Fosun is China's Johnson & Johnson Although this metaphor is not accurate, it can also show that the two companies are following different development routes Unlike Hengrui, which focuses on drug R & D and manufacturing, Fosun's business is more diversified, including drug manufacturing and R & D, medical services, medical devices and medical diagnosis, pharmaceutical distribution and retail, etc However, drug manufacturing and R & D is still the most important business component of the company, and there are many expected drugs in its R & D pipeline Next, take a look at 10 of the most potential drugs in research and see how the domestic pharmaceutical giant is looking forward to the new year     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im The drug is a biological analogue of lovastatin (commonly known as bevacizumab) In December 2015, the indication of the drug for metastatic colorectal cancer was approved by the clinical trial of the State Food and drug administration; in May 2016, the indication of the drug for non-small cell lung cancer was approved by the CFDA clinical trial In December 2016, Fosun launched phase I clinical trials of the drug in mainland China In November 2017, Fuhong Hanlin and Hanlin pharmaceutical submitted their clinical trial application to CFDA for the treatment of indications of wet age-related macular degeneration and diabetic retinopathy Up to now, only Avastin is the recombinant anti VEGF humanized monoclonal antibody injection in China According to statistics, the sales volume of bevacizumab in China in 2016 was about 680 million yuan, while its global sales volume in 2017 reached 7.184 billion US dollars In 2018, avidin's patent in Europe is about to expire At present, Fosun Pharmaceutical has invested more than 70 million yuan in research and development of the drug     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> Top9 fn-1501 this is a small molecule chemical drug for leukemia treatment In October 2017, it was approved by FDA for clinical research of new drugs; in January 2018, it was approved by CFDA for clinical trials Fn-1501 is an innovative small molecule chemical drug transferred by Fosun Pharmaceutical through China Pharmaceutical University and independently researched and developed by Fosun Fosun did not disclose more information about this drug in the announcement, but only mentioned that the new drug with the same target was first listed in the United States in 2017 According to the inquiry of Xinkangjie, on August 1, 2017, FDA approved idhifa of Xinji company It is suggested that fn-1501 is a small molecule inhibitor of isocitrate dehydrogenase 2 (idh2), which plays an important role in the tricarboxylic acid cycle It can inhibit the activities of many enzymes that promote cell proliferation At present, Fosun Pharmaceutical has invested more than 25 million yuan in research and development of the new drug     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> Top 8 recombinant anti-PD-L1 all human monoclonal antibody injection PD-1 / PD-L1 antibody is a research hotspot in the field of tumor treatment Compared with PD-1, the market of PD-L1 is still in the early stage of growth At present, tecentriq (atezolizumab), bavencio (avelumab) jointly developed by Merck and Pfizer, and imfinzi (durvalumab) of AstraZeneca are the recombinant anti-PD-L1 all human monoclonal antibody injections on the global market The global sales of recombinant anti-PD-L1 all human monoclonal antibody injection in 2017 was about 526 million US dollars, with a year-on-year growth rate of more than 250% At present, there is no approved anti-PD-L1 antibody drug in China Fosun's recombinant anti-PD-L1 all human monoclonal antibody injection was approved by CFDA for clinical research in November 2017   none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> Top7 hlx06 hlx06 is a monoclonal antibody targeting VEGFR2 Fosun has submitted the clinical trial application to CFDA for the treatment of solid tumors, and was accepted by the registration review in June 2017 In July 2017, henlix, a subsidiary of Fosun, submitted a clinical trial application to the US FDA Cyramza (ramucirumab) is one of the monoclonal antibody drugs with VEGFR2 target in foreign countries, but there is no similar drug with the same target in China According to the website of the drug evaluation center of the State Food and drug administration, Lilly has registered and carried out three clinical trials of cyramza in China, two of which are in phase III clinical trials; in addition, the recombinant anti VEGFR2 of Sichuan Kelun Botai biomedical Co., Ltd The clinical trial application of all human monoclonal antibody injection and recombinant anti vascular endothelial growth factor receptor 2 (VEGFR2) all human monoclonal antibody for injection of Shandong bubo Shenzhou Pharmaceutical Co., Ltd to the State Food and drug administration is still under approval Cyramza's global sales in 2017 were about $758 million By the end of 2017, Fosun had invested more than 55 million yuan in research and development of the new drug     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> Top 6 recombinant anti TNF α monoclonal antibody for Fosun injection is used to treat indications of rheumatoid arthritis and plaque psoriasis It was approved by clinical trials of State Food and Drug Administration in December 2015 and April 2017 respectively In December 2016, phase I clinical trial was launched in mainland China At present, TNF α inhibitors listed in China mainly include adamumumab injection, infliximab for injection, enacept for injection, recombinant human type II tumor necrosis factor receptor antibody fusion protein for injection (including yisaipu, qiangke and ambrano) TNF α inhibitors are the most sold drugs in the world because of their wide indications, including dozens of autoimmune diseases Sumil (adamumumab) had sales of US $18.43 billion in 2017, and enri and lake had sales of US $7.88 billion and US $6.32 billion, respectively The field of TNF α inhibitors is a huge and attractive cake in the eyes of major pharmaceutical companies to see who can eat much faster At present, Fosun has invested more than 70 million yuan in research and development of the new drug     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> top5 fcn-437c fcn-437c is an oral cyclin dependent kinase (CDKs) 4 and 6 inhibitor Cdks4 and 6 are the key regulatory factors of cell cycle, which can trigger cell cycle progression Fcn-437c can inhibit the proliferation of tumor cells by inhibiting cdks4 and 6, so as to achieve the effect of tumor treatment The new drug showed strong in vitro and in vivo activity, good pharmacokinetic characteristics and safety in preclinical research In July 2017, the new drug for solid tumor treatment was accepted by the clinical trial registration review of the State Food and drug administration CFDA approved this product for clinical trial in January 2018 There is no drug with independent intellectual property rights and the same target of the new drug on the market in mainland China The international drug with the same target is Pfizer's ibrance, with a sales volume of 3.13 billion US dollars in 2017 As of December 2017, Fosun has invested about 28 million yuan in research and development of the new drug     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> as of the end of 2017, the top 4 recombinant anti HER2 humanized monoclonal antibody for injection has been approved by CFDA for clinical trials in the treatment of metastatic breast cancer and gastric cancer At present, phase I clinical research has been completed in mainland China, and phase III clinical trials are being carried out The new drug is safe and equivalent to the original drug, trastuzumab In addition to mainland China, the drug has also been approved for clinical research in Ukraine, Poland and other European and American countries At present, HER2 inhibitors (used for metastatic breast cancer indications) are mainly trazumab, perforzumab, trazumab electromagnetic and lapatinib It is understood that Herceptin's sales reached $7534 million in 2017 At present, Fosun's R & D investment in this generic drug is about 250 million yuan     none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Top 30000 gliclazin is an sglt-2 inhibitor, mainly used for the treatment of type II diabetes The drug was initially developed by siro nabiochem Corp in 2014, Wanbang pharmaceutical, a subsidiary of Fosun Pharmaceutical, obtained the authorization of research and development, production and commercialization of Wan gliclazin in mainland China, and began systematic pharmaceutical and non clinical research In November 2017, Jiangsu Wanbang submitted a clinical trial application to the State Food and Drug Administration for the treatment of indications for type II diabetes The market capacity of diabetes drugs is huge, and the market is mainly occupied by insulin and its analogues However, in recent years, many new drugs of s-glt-2 inhibitors have entered the field of diabetes drugs, with AstraZeneca's Diglycine as the replacement